Radiation sensitizers: A selective review of molecules targeting DNA and non-DNA targets

Journal of Nuclear Medicine

Volumn 46, Issue 1 SUPPL., 2005, Pages

  Kvols, Larry K ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

5 fluorouracil; Epidermal growth factor inhibitors; Gemcitabine; Platinum; Radiation sensitizers; Topoisomerase; Vascular endothelial growth factor inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN DERIVATIVE; CANERTINIB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; CYTARABINE DERIVATIVE; DNA; DNA TOPOISOMERASE; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; GEFITINIB; GEMCITABINE; IRINOTECAN; L 778123; NONSTEROID ANTIINFLAMMATORY AGENT; OXALIPLATIN; PLATINUM DERIVATIVE; PROSTAGLANDIN DERIVATIVE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RADIOSENSITIZING AGENT; TOPOTECAN;

CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESEARCH; CLINICAL TRIAL; DISEASE PREDISPOSITION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; PRIORITY JOURNAL; REVIEW; TOXICITY; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR VASCULARIZATION; ANIMAL; DRUG DELIVERY SYSTEM; DRUG EFFECT; GENETICS; METHODOLOGY; MULTIMODALITY CANCER THERAPY; NEOPLASM;

ANIMALS; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DNA, NEOPLASM; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; RADIATION-SENSITIZING AGENTS;

EID: 14844353135     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Heidelberger C, Griesbach L, Cruz O, Schnitzer RJ, Grunberg E. Fluorinated pyrimidines. VI. Effects of 5-fluorouridine and 5-fluoro-2′- deoxyuridine on transplanted tumors. Proc Soc Exp Biol Med. 1958;97:470-475.
2. Moertel CG, Reitemeier RJ, Childs DS Jr, Colby MY, Holbrook MA. Combined 5-fluorouracil and supervoltage radiation therapy in the palliative management of advanced gastrointestinal cancer: a pilot study. Mayo Clin Proc. 1964;39:767-771.
3. Nigro ND, Vaitkevicius VK, Considine B Jr. Combined therapy for cancer of the anal canal: a preliminary report - 1974. Dis Colon Rectum. 1993;36:709-711.
4. Adelstein DJ. Recent advances of chemoradiation in the management of locally advanced head and neck cancer. Curr Opin Oncol. 1998;10:213-218.
5. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350:1937-1944.
6. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 1999;281:1623-1627.
7. Herskovic A, Martz K, Al Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326:1593-1598.
8. Furuse K, Fukuoka M, Kawahara, et al. A phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol. 1999;17:2692-2699.
9. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725-730.
10. Penberthy DR, Rich TA, Shelton CH III, et al. A pilot study of chronomodulated infusional 5-fluorouracil chemoradiation for pancreatic cancer. Ann Oncol. 2001;12:681-684.
11. Evans DB, Wolff RA, Crane CH. Neoadjuvant strategies for pancreatic cancer. Oncology (Huntingt). 2001;15:727-737.
12. Cooperman AM. Pancreatic cancer: the bigger picture. Surg Clin North Am. 2001;81:557-574.
13. Ryan DP, Compton CC, Mayer RJ. Medical progress: carcinoma of the anal canal. N Engl J Med. 2000;342:792-800.
14. Thomas GM. Improved treatment for cervical cancer: concurrent chemotherapy and radiotherapy. N Engl J Med. 1999;340:1198-1200.
15. Lawrence TS, Tepper JE, Blockstock AW. Fluoropyrimidine-radiation interactions in cells and tumors. Semin Rad Oncol. 1997;4:260-266.
16. Whittington R, Newberg D, Tester WJ, et al. Protracted intravenous fluorouracil infusion with radiation therapy in the management of localized pancreaticobiliary carcinoma: a phase I Eastern Cooperative Oncology Group Trial. J Clin Oncol. 1995;13:227-232.
17. Rich TA. Infusional chemoradiation for rectal and anal cancers. Oncology. 1999;13:131-134.
18. Richmond RC. Toxic variability and radiation sensitization by dichlorodiamine platinum (II) complexes in salmonella typhimurium cells. Radiat Res. 1984;99:596-608.
19. Amorino GP, Freeman ML, Carbone DP, et al. Radiopotentiation by the oral platinum agent, JM216: role of repair inhibition. Int J Radiat Oncol Biol Phys. 1999;44:399-405.
20. Yang LX, Douple EB, Wang HJ. Irradiation enhances cellular uptake of carboplatin. Int J Radiat Oncol Biol Phys. 1995;33:641-646.
21. Servidei T, Ferlini C, Riccardi A, et al. The novel trinuclear platinum complex BBR3464 induces a cellular response different from cisplatin. Eur J Cancer. 2001;37:930-938.
22. Moreland NJ, Illand M, Kim YT, et al. Modulation of drug resistance mediated by loss of mismatch repair by the DNA polymerase inhibitor aphidicolin. Cancer Res. 1999;59:2102-2106.
23. Jassem J. Combined chemotherapy and radiation in locally advanced non-small cell lung cancer. Lung Cancer. 2001;34(suppl 2):181-183.
24. Rose PG. Chemoradiotherapy for cervical cancer. Eur J Cancer. 2002;38:270-278.
25. Browman GP, Hodson DI, Mackenzie RJ, et al. Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: a systematic review of the published literature with subgroup analysis. Head Neck. 2001;23:579-589.
26. Freyer G, Bossard N, Romestaing P, et al. Addition of oxaliplatin to continuous fluorouracil, 1-folinic acid, and concomitant radiotherapy in rectal cancer: the Lyon R 97-03 phase I trial. J Clin Oncol. 2001;19:2433-2438.
27. Moore M, Andersen J, Burris H, et al. A randomized trial of gemcitabine versus 5FU as first-line therapy in advanced pancreatic cancer [abstract]. Proc Am Soc Clin Oncol. 1995;14:199.
28. Rothenberg ML, Moore MJ, Cripps MC. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol. 1996;14:347-353.
29. Sandler AB, Ansari R, McClean J. A Hoosier Oncology Group phase II study of gemcitabine plus cisplatin in non-small-cell lung cancer [abstract]. Proc Am Soc Clin Oncol. 1995;14:357.
30. Carmichael J, Allerheiligen S, Walling J. A phase I/II study of gemcitabine and carboplatin in NSCLC [abstract]. Proc Am Soc Clin Oncol. 1995;14:351.
31. Shewach DS, Hahn TM, Chang E, et al. Metabolism of 2′,2′- difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res. 1994;54:3218 -3223.
32. Ostruszka LJ, Shewach DS. The role of cell cycle progression in radiosensitization by 2′, 2′ -difluoro-2′-deoxycytidine. Cancer Res. 2000;60:6080-6088.
33. Lawrence TS, Blackstock AW, McGinn C. The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Semin Rad Oncol. 2003;13:13-21.
34. Chen AY, Choy H, Rothenberg M. DNA topoisomerase I-targeting drugs as radiation sensitizers. Oncology (Huntingt). 1999;5:39-46.
35. Chen AY, Okunieff P, Pommier Y, et al. Mammalian DNA topoisomerase I mediates the enhancement of radiation cytotoxicity by camptothecin derivatives. Cancer Res. 1997;57:1529-1536.
36. Huang SM, Harari PM. Epidermal growth factor inhibition in cancer: biology, rationale and preliminary clinical results. Invest New Drugs. 1999;17:259-269.
37. Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics and tumor angiogenesis. Clin Cancer Res. 2000;6:2166-2174.
38. Brunner TB, Gupta AK, Shi Y, et al. Farnesyltransferase inhibitors as radiation sensitizers. Int J Radiat Biol. 2003;79:569-576.
39. Davis TW, Hunter N, Trifan O, Milas L, Masferrer JL. COX-2 inhibitors as radiosensitizing agents for cancer therapy. Am J Clin Oncol. 2003;26:S58-S61.